Skip to main content

Table 2 Relative risk of all-grade and high-grade (grade ≥ 3) hypertension of several VSP inhibitor agents, described in meta-analyses

From: Hypertension in cancer patients treated with anti-angiogenic based regimens

  All grade hypertension High grade hypertension
  RRa 95 % CI p Value RRa 95 % CI p Value
Bevacizumab [33] 3.02 2.24–4.07 <0.001 5.28 4.15–6.71 0.001
Sunitinib [52] 3.44 0.62–19.15 0.16 22.72 4.48–115.29 <0.001
Axitinib [38] 3.00 1.29–6.97 0.01 1.71 1.21–2.43 0.003
Sorafenib [62] 3.07 2.05–4.60 <0.01 3.31 2.21–4.95 <0.01
Pazopanib [65] 4.97 3.38–7.30 <0.001 2.87 1.16–7.11 0.023
Lenvatinib [69] 7.44 4.31–12.85 <0.001 18.2 5.90–56.32 <0.001
Vandetanib [36] 5.10 3.76–6.92 <0.001 8.06 3.41–19.04 0.001
Regorafenib [74] 3.76 2.35–5.99 <0.001 8.39 3.10–22.71 0.001
  1. Abbreviations: RR relative risk, CI confidence interval
  2. a Relative risk of new onset hypertension during trial period in interventional group compared to control